Neoplasms

Digestive System Diseases

All Conditions

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Antineoplastic Agents

All Drugs and Chemicals

Amino Acids

Bevacizumab

Capecitabine

Erlotinib Hydrochloride

Antineoplastic Agents, Immunological

Angiogenesis Inhibitors

Growth Inhibitors

Antimetabolites

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Tyrosine

bevacizumab 7.5 mg/kg body weight every third week, erlotinib 150 mg daily

bevacizumab, erlotinib

bevacizumab 7.5 mg/kg body weight every third week

bevacizumab

bevacizumab 7.5 mg/kg body weight every third week.

low dose capecitabine

Patients with metastatic colorectal cancer will be treated with chemotherapy according to investigators choice. In addition to chemotherapy treatment, treatment with bevacizumab will be given concomitantly. This treatment will continue during 18 weeks. Meanwhile, the patients KRAS status will be tested. After having fulfilled these 18 weeks of induction treatment, patients who has responded (complete response/partial response versus stable disease) will be randomized to maintenance treatment. Patients with KRAS WT will be randomized to either bevacizumab alone, or to bevacizumab and erlotinib. Patient with KRAS mutation will be randomized to either bevacizumab, or metronomic capecitabine. Translational research is performed, with purpose to find predictive factors in blood and tumor tissue.

Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.

Hoffmann-La Roche

Lund University Hospital

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.	NCT01229813	Colorectal Canc...	bevacizumab, er... bevacizumab bevacizumab low dose capeci...	18 Years -	Lund University Hospital
Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.	NCT01229813	Colorectal Canc...	bevacizumab, er... bevacizumab bevacizumab low dose capeci...	18 Years -	Lund University Hospital

Spots Global Cancer Trial Database for low dose capecitabine